Altimmune Investors Drop Suit Over Liver Drug Trial, Stock Drop

Altimmune Inc. investors voluntarily dismissed claims it overhyped topline trial results of a liver disease treatment before sharing one of its goals lacked statistical significance.

Judge Theodore D. Chuang ordered the case closed in the US District Court for the District of Maryland Nov. 26, the same day the investors said they were dropping their lawsuit with the ability to refile. The proposed class action followed Altimmune’s announcement that while there appeared to be a positive trend in improvement on liver scarring, known as fibrosis, from the drug pemvidutide, there wasn’t a statistically significant difference compared to a placebo group ...